US regulators have instructed Novo Nordisk and Eli Lilly to remove label warnings about suicidal thoughts from their popular weight-loss medications. The Food and Drug Administration (FDA) said a comprehensive review found no increased suicide risk among users of GLP-1 drugs for obesity, including Wegovy, Saxenda, and Zepbound.
A preliminary review in January 2024 had shown no link between the drugs and suicidal thoughts, but officials then could not rule out a small risk. The new analysis puts those concerns to rest, the FDA stated.
The agency noted that other GLP-1 receptor agonists approved for diabetes treatment carried no such warnings. “Today's FDA action will ensure consistent messaging across the labeling for all FDA-approved GLP-1 RA medications,” officials said.
